Vanda Pharmaceuticals Inc. (VNDA)
Nasdaq: VNDA · Pharmaceutical Preparations · Washington, DC · filing with the SEC since 2005
Who owns Vanda Pharmaceuticals Inc.
As filed with the SECHolders of 5% or more
5
Blackrock, Inc. holds 8.1% of Common Stock, as its SCHEDULE 13G/A filed Feb 7, 2025 says.
Directors and officers
14
report now, of 23 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 5 named at left.
Holders of 5% or moreshare of the class, as filed
Blackrock, Inc.
SCHEDULE 13G/A · filed Feb 7, 2025 · Common Stock · 15.6% in Feb 5, 2025
Millennium Management LLC
SCHEDULE 13G/A · filed Oct 9, 2026 · Common Stock, par value $0.001 per share · 5.6% in Aug 19, 2026
BlackRock Portfolio Management LLC
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock · 4.2% in Apr 29, 2026
AQR Capital Management, LLC
SCHEDULE 13G · filed Aug 13, 2026 · Common Stock, par value $0.001 per share
State Street Corporation
SCHEDULE 13G · filed May 12, 2026 · COMMON STOCK
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What VNDA reports owning in othersstakes of 5% or more, and other ties
Vanda Pharmaceuticals Inc. reports no stake in another company in the record.
Insider tradesForm 4
6sales
3purchases
0sales on a scheduled plan
6people selling
$2.8Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Nov 5, 2025 to Nov 5, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 5, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 29 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Polymeropoulos Mihael Hristos | President and CEO | 1 | $1.3M | 0 | 0 | $0 |
| Moran Kevin Patrick | SVP, CFO & Treasurer | 1 | $400,000 | 0 | 0 | $0 |
| Birznieks Gunther | SVP, Business Development | 1 | $400,000 | 0 | 0 | $0 |
| Williams Timothy | SVP & General Counsel | 1 | $400,000 | 0 | 0 | $0 |
| Wijkstrom Joakim | SVP, Chief Marketing Officer | 1 | $300,000 | 0 | 0 | $0 |
| Honore Tage | director | 1 | $200,000 | 0 | 0 | $0 |
| Duncan Charles Cliff | director | 0 | $0 | 0 | 3 | $0 |